Skip to main content
Clinical Trials/NCT06000748
NCT06000748
Terminated
Phase 2

NEPH-ROSIS (NEPHrology in CirRhOSIS) Pilot Trial: A Trial to Treat Acute Kidney Injury Among Hospitalized Cirrhosis Patients

University of California, San Francisco1 site in 1 country6 target enrollmentFebruary 1, 2024

Overview

Phase
Phase 2
Intervention
MAP-Target Algorithm
Conditions
Acute Kidney Injury
Sponsor
University of California, San Francisco
Enrollment
6
Locations
1
Primary Endpoint
Differences in mean arterial pressure.
Status
Terminated
Last Updated
11 months ago

Overview

Brief Summary

The goal of this pilot, randomized, single-blind clinical trial is to estimate the effect size of a high and low mean arterial pressure (MAP)-target algorithm among cirrhosis patients hospitalized with acute kidney injury. The main aims to answer are: • Does an algorithm that has low (<80 mmHg) and high (≥80) MAP-targets lead to significant differences in mean arterial pressure? • Are there any serious adverse events (e.g., ischemia) in a high blood pressure algorithm as compared to a low blood pressure algorithm? • Are there any differences in the incidence of AKI reversal in the high v. low MAP-target groups? Participants will be: 1) Randomized to a clinical algorithm that will either target a low (<80 mmHg) or high (≥80 mmHg) MAP. 2) Depending on their group, investigators will titrate commonly used medications to a specific MAP target. Researchers will compare the high and low MAP-target groups to see if these algorithms lead to significant changes in MAP, if they have any impact on AKI reversal, and if there are any adverse events in the high MAP-target group.

Registry
clinicaltrials.gov
Start Date
February 1, 2024
End Date
July 31, 2024
Last Updated
11 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Hospitalized patients with decompensated cirrhosis, defined as a Child-Pugh Score ≥ 7
  • Acute Kidney Injury: a ≥50% increase in sCr from an outpatient baseline sCr measured 7 to 365 days prior to admission

Exclusion Criteria

  • Patients without a baseline (7 - 365 days prior to AKI development) sCr measurement;
  • Patients who are already on kidney replacement therapy (KRT) at the time of enrollment;
  • Patients with an oxygen requirement greater than 6L via nasal cannula;
  • Patients with a serum creatinine level exceeding 5 mg/dL.

Arms & Interventions

Low MAP-Target

This group will be randomized to a treatment algorithm that utilizes a low MAP-target (\<80 mmHg) to determine if titration of vasoconstrictors is needed.

Intervention: MAP-Target Algorithm

High MAP-Target

This group will be randomized to a treatment algorithm that utilizes a high MAP-target (≥80 mmHg) to determine if titration of vasoconstrictors is needed.

Intervention: MAP-Target Algorithm

Outcomes

Primary Outcomes

Differences in mean arterial pressure.

Time Frame: 14 days.

The investigators will determine if a high, as compared to a low, MAP-target algorithm leads to significantly different changes in MAP. This will be completed by comparing the change in MAP from the baseline to the completion of the study.

Secondary Outcomes

  • Acute kidney injury reversal.(14 days)

Study Sites (1)

Loading locations...

Similar Trials